Answers are grounded in this paper and cite their sources.
The introduction of transcatheter aortic valve implantation (TAVI) offered a new therapy to patients with severe aortic stenosis who are not candidates for surgical valve replacement (SAVR)1,2 or who are at high risk for complications due to surgery.3 TAVI has proven to be similar to SAVR with respect to disabling stroke or death in patients at intermediate clinical risk.4 A recent report from the PARTNER 3 trial indicates that, in patients at low surgical risk, the rate of the composite of death, stroke, or rehospitalization at 1 year was significantly lower with TAVI than with SAVR.
No takes yet. Share an insight, caveat, or question.
Oury et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: